Physician profile
Sharon Laughlin
NPI 1689638348
$7,597.78
in general payments reported to CMS, 2019-2025
25 companies · $1,517 in 2025
The $1,517 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $611 · 2020: $774 · 2021: $803 · 2022: $2,405 · 2023: $661 · 2024: $827 · 2025: $1,517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,985 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,984.93 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $1,978.31 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $1,067.24 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $700.61 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $440.00 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $417.58 | 2019-2025 | |
| Abbvie INC. | $415.22 | 2020-2024 | |
| Novo Nordisk INC | $369.66 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $310.27 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $241.73 | 2023-2025 | Otezla, Repatha, Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $209.96 | 2019-2023 | Eliquis |
| Corcept Therapeutics | $204.83 | 2024-2025 | Korlym |
| Janssen Pharmaceuticals, INC | $187.57 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $164.93 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $160.39 | 2024-2025 | |
| Biohaven Pharmaceuticals, INC. | $138.86 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $134.39 | 2023-2025 | Cologuard Collection Kit |
| Eisai INC. | $100.15 | 2020-2021 | |
| Allergan, INC. | $93.44 | 2019-2020 | |
| Abbott Laboratories | $83.14 | 2022-2024 | Freestyle Libre 3 |
| Intuitive Surgical, INC. | $56.55 | 2025 | |
| Merz North America, INC. | $33.57 | 2024-2025 | |
| Averitas Pharma INC. | $30.00 | 2024 | Qutenza |
| Therapeuticsmd, INC. | $22.73 | 2019 | |
| Sanofi-Aventis U.S. LLC | $22.18 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Laughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.